TGFB1 and osteogenesis imperfecta: Importantly, treating OIM/OIM or wild-type mice with soluble activin receptor has been shown to increase trabecular bone volume and improve cortical bone geometry and biochemical strength further suggesting that inhibiting effectors of TGFβ signalling may be a useful method of alleviating the adverse bone effects associated with OI without adversely affecting some related cell types (Jeong et al., 2018).